Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neuropilin-1 receptor antagonists - Ark Therapeutics

Drug Profile

Research programme: neuropilin-1 receptor antagonists - Ark Therapeutics

Alternative Names: EG0048; EG012; EG012-014; EG01257; EG014; EG3287

Latest Information Update: 23 Nov 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ark Therapeutics
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Neuropilin-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 08 Nov 2012 Discontinued - Preclinical for Solid tumours in United Kingdom (unspecified route)
  • 22 May 2012 Preclinical development is ongoing in United Kingdom
  • 11 Mar 2011 The neuropilin-1 receptor antagonists programme is available for licensing \www.arktherapeutics.com\
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top